Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C16H23N3O4 · CH4O3S
CAS Number:
Molecular Weight:
417.48
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
Quality Level
form
solid
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
application(s)
forensics and toxicology
pharmaceutical (small molecule)
veterinary
format
neat
SMILES string
CS(O)(=O)=O.CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1
InChI
1S/C16H23N3O4.CH4O3S/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18;1-5(2,3)4/h7-10H,2-6,11H2,1H3,(H4,17,18,19);1H3,(H,2,3,4)
InChI key
DNTNDFLIKUKKOC-UHFFFAOYSA-N
General description
Gabexate mesylate is a non-antigenic synthetic inhibitor of trypsin-like serine proteinases, which finds therapeutic applications in the treatment of disseminated intravascular coagulation and pancreatitis. It also plays the role of an anticoagulant in hemodialysis therapy.
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
Analytical Enzyme Chymotrypsin: Chymotrypsin is produced in the acinar cells of the pancreas as the inactive precursor, chymotrypsinogen.
Dalya M Lateef et al.
Peptides, 32(6), 1289-1295 (2011-04-02)
Camostat mesilate (or mesylate) releases endogenous cholecystokinin (CCK) or CCK-58, the only detectable endocrine form of CCK in the rat, and reduces cumulative food intake by activating CCK(1) receptor. However, the literature lacks meal pattern analysis and an appropriate dose-response
Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug.
Erba F, et al.
Biochemical Pharmacology, 61(3), 271-276 (2001)
Manabu Hayata et al.
American journal of physiology. Renal physiology, 303(8), F1126-F1135 (2012-07-27)
The number of the chronic renal failure (CRF) patients is increasing explosively. Hypertension, proteinuria, inflammation, fibrosis, and oxidative stress are intertwined in a complicated manner that leads to the progression of CRF. However, the therapeutic strategies to delay its progression